Compare Supplements

Side-by-side comparison of 1 supplements

Efp4.3

Efpeglenatide

Limited safety

Evidence

Evidence Score4.3/10

Studies: 7

Meta-analyses: 2

Dosage & timing

Dosage:

INVESTIGATIONAL — NO approved or consumer dose. In trials, efpeglenatide was given as a once-weekly subcutaneous injection, titrated up to 4-6 mg (AMPLITUDE-O used 4 and 6 mg) with gradual escalation to limit GI side effects. Not for self-administration; it is an unapproved, unmarketed investigational drug.

Best Time:

Any time

Can take on empty stomach

Form:

Once-weekly subcutaneous injection (investigational only)

What you'll notice

❤️ Reduced major cardiovascular events (MACE)positive

Over ~1.8 years (trial follow-up)

🫘 Reduced kidney-outcome eventspositive

Over ~1.8 years

🩸 Improved glycemic controlpositive

Weeks to months

Safety

Limited safety

Contraindications:

Not a dietary supplement and not an approved/marketed drug — investigational; do not self-source grey-market vials
Personal/family history of medullary thyroid carcinoma or MEN 2 (expected GLP-1-class thyroid C-cell warning)
History of pancreatitis

Drug Interactions:

Oral medications (delayed gastric emptying)
Insulin / insulin secretagogues (sulfonylureas)
Other GLP-1 / incretin drugs

Side Effects:

Nausea / vomitingDiarrhea / constipation / bloatingTreatment discontinuation due to GI events

Want to compare more supplements?

Loading comparison...